| DRUG WATCH |
|
| Year : 2018 | Volume
: 50
| Issue : 5 | Page : 284-286 |
Rare occurrence of hand-foot syndrome due to paclitaxel: A rare case report
Pritam S Kataria1, Pradip P Kendre1, Apurva A Patel2, Nahush Tahiliani1, Vijay Bhargav1, Honey Parekh1
1 Department of Medical and Paediatric Oncology, GCRI, Ahmedabad, Gujarat, India
2 Department of Medical Oncology, GCRI, Ahmedabad, Gujarat, India
Correspondence Address:
Dr. Apurva A Patel
Department of Medical Oncology, GCRI, Ahmedabad - 380 016, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.IJP_547_17
Hand-foot syndrome (HFS) is a relatively frequent adverse reaction to certain anticancer drugs. HFS is a type of dermatitis which has been most commonly described with 5-fluorouracil and capecitabine. However, HFS with paclitaxel is rare and has been reported sparingly in the literature. A 52-year-old male patient with recurrent carcinoma of the buccal mucosa was started on palliative chemotherapy regimen, injection paclitaxel (175 mg/m2) in combination with injection carboplatin. On post-chemotherapy day 13, the patient started developing pain, dysesthesia followed by bullae formation, and desquamation over palms and soles. Clinically, the patient had Grade 3 HFS characterized by symmetrical, tender skin lesions over the dorsal aspect of palms, and soles with desquamation necessitating interruption of treatment. Therefore, this case has been presented to be cognizant with this rare form of side effect with one of the most commonly used drug in oncology.
[FULL TEXT] [PDF]*
|
